Strand Life Sciences, a Reliance Industries subsidiary, announced the launch of its advanced proteomics capabilities, marking a milestone in its large-scale multi-omics research in India and South Asia, it said.

The capability enabled by the ‘OlinkTM Explore HT’ platform helps measure over 5,400 protein biomarkers from just 2 μL of sample — roughly one-twenty-fifth of a single drop of blood — allowing Strand to deliver integrated proteomics, genomics, and clinical insights for advanced research and drug discovery, it said.

Every living cell produces thousands of proteins — the molecular machines that carry out virtually every biological function in the body, from fighting infection to regulating metabolism, the company said.

And proteomics is the study of these proteins, and their role in health and disease. “It tells us what is actually being built and in what quantities — making it one of the most direct windows into the biology of disease,” the note said.

Next-generation proteomics platforms have enabled the simultaneous analysis of thousands of proteins from a single, small blood sample. The result is a richer, faster, and far more actionable picture of disease biology — one that supports more precise treatment selection, and the discovery of new drug targets, it added.

Guiding treatment  

Strand has completed a proteomics project for a biopharma partner, involving patients with chronic kidney disease, demonstrating the platform’s potential in translational research and clinical studies, it said.

For pharmaceutical and biotechnology companies, this capability cuts short time, for example – “research programmes that once required time intensive sequential investigation can now be compressed into integrated, large-scale studies,” it said. For clinicians and patients, the promise is equally significant, Strand said.

“Biomarkers identified through proteomics can guide treatment decisions with greater confidence and open new frontiers in precision medicine.”

Dr Ramesh Hariharan, Chief Executive, Strand Life Sciences, said: “With OlinkTM Explore HT, Strand is bringing one of the world’s most advanced proteomics platforms to India and the region. By combining this with established strengths in genomics, bioinformatics, and clinical partnerships, Strand aims to deliver end-to-end multi-omics programmes and enable faster, more impactful discovery.” Through its clinical partners, the company enables studies across therapeutic areas, including oncology, nephrology, metabolic diseases, and rare disorders. Strand is engaging with global academic, pharmaceutical, and biotechnology organisations seeking to conduct discovery, validation, and translational research programmes at scale, it said.

Published on May 19, 2026